Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 21-30 of 38 for Clostridium difficile infection

Edit search filters
  1. Microbiota Restoration Therapy For Recurrent Clostridium Difficile Infection (PUNCHCD3)

    Rochester, MN

  2. Trials Evaluating Oral Full-Spectrum Microbiota™ (CP101) In Subjects With Recurrence Of Clostridium Difficile Infection

    Rochester, MN

  3. Open-Label Extension Of CP101 Trials Evaluating Oral Full-Spectrum Microbiota™ (CP101) In Subjects With Recurrence Of Clostridium Difficile Infection

    Scottsdale/Phoenix, AZ

  4. A Study Of VE303 For Prevention Of Recurrent Clostridium Difficile Infection

    Scottsdale/Phoenix, AZ

  5. A Study To Compare Ridinilazole Versus Vancomycin Treatment For Clostridium Difficile Infection (CDI)

    Rochester, MN

  6. ECOSPOR III - SER-109 Versus Placebo In The Treatment Of Adults With Recurrent Clostridium Difficile Infection

    Rochester, MN

  7. ECOSPOR IV: An Open-Label Extension Of Study SERES 0012 Evaluating SER-109 In Subjects With Recurrent Clostridium Difficile Infection

    Rochester, MN

  8. Efficacy, Safety, And Tolerability Of Oral Full-Spectrum Microbiota® (CP101) In Subjects With Recurrence Of Clostridium Difficile Infection (PRISM3)

    Scottsdale/Phoenix, AZ

  9. Kinetics of Clostridium Difficile Toxin PCR Positivity and Prediction of Recurrent Infection following Metronidazole or Vancomycin Therapy

    Rochester, MN

  10. A Study to Improve Treatment of Clostridium Difficile Infection and using Information Technology to Improve the Care of Patients with Severe Clostridium Difficile Infection

    Rochester, MN

.

Mayo Clinic Footer